571 results about "Diagnostic marker" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of secretory lactase-like protein (LCTL) as a diagnostic marker in preparation of a diagnostic kit for chronic kidney diseases. According to the present invention, the secretory form of the LCTL is found for the first time, the secretory LCTL content in the human serum is detected by using the existing commercial ELISA kit for the first time, and the further research finds that the secretory LCTL content in the serum of the chronic kidney disease patient is significantly reduced compared with the normal person; and the content of the LCTL in the serum is obviously related to the renal function impairment degree and proteinuria degree of the patient, so that the application of the secretory LCTL in preparing the biomarker for diagnosing the chronic kidney disease is provided for the first time. The invention provides a new method for chronic kidney disease diagnosis, and has important clinical significance and commercial value.

The invention discloses a novel tsRNA high-sensitivity detection kit based on CRISPR (clustered regularly interspaced short palindromic repeats) / Cas13a-Cas14a, and belongs to the field of tumor marker detection. The tsRNA (tRNA-derived small RNA) is a diagnostic marker which is found recently and has great potential. In order to realize the clinical transformation of tsRNA as soon as possible, the tsRNA detection kit is developed on the basis of nuclease P1 combined with CRISPR / Cas13a-Cas14a linkage dual systems, and comprehensive, ultra-sensitive, high-specificity, low-cost and rapid tsRNA detection is realized through multiple signal amplification. Compared with the traditional technology, the sensitivity of the method is improved by 105-107 times, 1% of tsRNA in the mixture can be detected, and the method has more advantages in clinical application. Therefore, a new scheme is provided for application of the tsRNA in clinical diagnosis of diseases, and meanwhile, a reliable technology is provided for mechanism research of the tsRNA in occurrence and development of the diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a macrophage Angulin-1 gene and / or an Angulin-1 protein in preparation of medicines and diagnostic products for preventing and / or treating atherosclerosis and related diseases. Research finds that plaque and necrotic core areas of an atherosclerosis animal model are remarkably increased due to macrophage Angulin-1 gene knockout, and disease development is promoted; and the recovery of the expression level of Angulin-1 significantly inhibits the development of lesion. Cell experiments show that Angulin-1 reduces intake of oxidized low-density lipoprotein by down-regulating expression of macrophage LOX-1, so that formation of foam cells is inhibited. Therefore, the macrophage Angulin-1 can be used as an atherosclerosis drug target, a gene therapy target gene and an auxiliary diagnosis marker, and a new theoretical basis and an intervention strategy are provided for prevention and treatment of the disease.

The invention discloses a rheumatoid arthritis diagnosis product and system and application thereof, and relates to the technical field of rheumatoid arthritis. The diagnostic marker comprises calcium, a ratio of arginine to ornithine, a ratio of phenylalanine to tyrosine, an anti-cyclic citrullinated peptide antibody and lysine. The invention provides a biomarker capable of accurately diagnosing rheumatoid arthritis RA, which comprises five indexes, namely calcium, the proportion of arginine to ornithine, the proportion of phenylalanine to tyrosine, an anti-cyclic citrullinated peptide antibody (anti-CCP) and lysine. The five indexes have the technical advantages of few indexes and excellent diagnosis performance. A diagnosis model constructed based on the five indexes has good sensitivity, specificity and accuracy. The kit can be used for diagnosis of rheumatoid arthritis.

The invention provides a diagnostic marker for systemic lupus erythematosus and application of the diagnostic marker, and belongs to the technical field of biological medicine. The diagnostic marker is at least one protein of PDGFA (Platelet Derivative Growth Factor Amplification), APOD (Adenosine Polymerase Chain Reaction), CFHR5, AMDHD1 and SCGB3A1; the amino acid sequence of the PDGFA is as shown in SED ID NO. 1; the amino acid sequence of the APOD is as shown in SED ID NO. 2; the amino acid sequence of the CFHR5 is as shown in SED ID NO.3; the amino acid sequence of AMDHD1 is as shown in SED ID NO. 4; and the amino acid sequence of the SCGB3A1 is as shown in SED ID (Sequence of Identification) NO.5. According to the present invention, the five proteins are adopted as the SLE disease diagnosis biomarker independently or in the combination manner, such that advantages of high accuracy, high sensitivity and high specificity are provided, and the new target spot is provided for the diagnosis, the intervention improvement and the like of the SLE patient.

The invention relates to a molecular model established based on proteomics detection serum specimens and used for assisting in evaluating the renal injury progress of diabetic nephropathy as well as a construction method and application of the molecular model, new disease diagnosis markers can be found, and an existing disease diagnosis system can be optimized; according to the technical scheme, a proteomics technology is combined with various medical diagnosis technologies such as experiments and images through research thinking logic of evidence-based medicine and clinical epidemiology so as to diagnose whether a patient suffers from diseases or not and identify different diseases, and the molecular model is formed by combining proteins P23396 + P0CG47 + Q9NYQ8 + P63241, according to the present invention, the protein composition in the sample is detected by using the high-throughput mass spectrometry means, the difference of the diabetic nephropathy disease group and the non-disease group on the proteomics level is compared, the biomarker for the disease progress auxiliary evaluation model construction is screened, and the new scheme is provided for the disease progress auxiliary evaluation of the diabetic nephropathy.

A use of a GPR1 as a target in preparing an endometriosis-related diagnostic and / or therapeutic formulation, relating to the technical field of biomedicine. The present invention provides a use of a GPR1 target as a diagnostic marker in preparing a reagent or kit for diagnosing endometriosis. The endometriosis is selected from one of uterosacral ligament endometriosis, peritoneal endometriosis, rectovaginal endometriosis, deep infiltrating endometriosis, and ovarian endometriosis. The present invention discovers that the expression of the GPR1 is significantly increased in endometriosis tissues and cells, indicating that the GPR1 can be used as a diagnostic marker for endometriosis. It has been discovered in in-vitro and in-vivo models that GPR1 knockout significantly inhibits the abilities of hEM15A cells to proliferate, migrate, and invade and the growth of ectopic foci in animals, indicating that the GPR1 can be used as a new intervention target for clinically treating endometriosis.

The invention relates to the technical field of diagnosis markers and diagnosis methods for mental diseases of children and adolescents, in particular to a plasma metabolism diagnosis marker and diagnosis system for depression of children and adolescents. The plasma metabolism diagnosis marker comprises at least one of cyclic adenosine monophosphate, methylpyridine, unsaturated undecylenyl carnitine, histidine, prolyl hydroxyproline, tryptophan and glucuronic acid. According to the scheme, non-target metabonomics data is analyzed, and seven candidate diagnostic markers for depression of children and adolescents are screened and determined from common differential metabolites. Then, through targeted metabonomics research, diagnostic markers and combinations thereof with ideal diagnostic effects are determined, and then a diagnostic model is constructed. And a sex factor is also incorporated into the diagnosis model, so that the diagnosis effect is further improved. According to the technical scheme, the technical problem that in the prior art, reliability and popularization potential of depression plasma metabolism biomarkers of children and adolescents are not ideal can be solved, and the depression plasma metabolism biomarkers have ideal popularization and application prospects.

The invention relates to a metabolic biomarker for predicting the cardiovascular disease risk of a patient with senile subclinical hypothyroidism and application of the metabolic biomarker. The marker comprises inosine, arachidonic acid, arginine, phenylalanine and glycocholic acid. According to the method, metabolite information of each plasma sample in a research queue is obtained by establishing an elderly SCH and concurrent CVD crowd queue and detecting by adopting a high performance liquid chromatography-mass spectrometry technology, and a targeted metabolic content map is established. According to the matrix expression of the metabolic marker, in combination with clinical follow-up visit data, a model is constructed by using machine learning Lasso-cox, and a clinical prediction model of the CVD risk of the elderly SCH patient is constructed to guide precise diagnosis and treatment of the elderly SCH. The invention further provides a kit containing the diagnostic marker suitable for predicting the CVD risk of the elderly SCH, and the kit can be used for predicting the CVD risk of the elderly SCH.

The invention belongs to the technical field of biomedicine, and particularly relates to application of GPR161 as an acute distress syndrome diagnostic marker and a therapeutic target. Experiments prove that the expression level of GPR161 in peripheral blood mononuclear cells of a patient with the acute respiratory distress syndrome is remarkably increased, and the expression quantity of the GPR161 is positively correlated with the severity of the disease, so that the GPR161 gene or GPR161 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of the acute respiratory distress syndrome; a reagent for inhibiting GPR161 gene expression or protein activity can be used for preparing a medicine for treating the acute respiratory distress syndrome. The invention provides a new strategy for diagnosis, monitoring and targeted drug development of ARDS, and has important clinical application value.

The invention discloses an early diagnosis marker for B-cell lymphoma, a cross-species screening method based on lamprey and application, and relates to the technical field of molecular diagnosis. In the prior art, tissue biopsy is strong in invasiveness, and a traditional marker is low in early detection rate; in order to solve the problems that a large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large- When the expression quantity of the gene in a sample is greater than or equal to 1.8 times of that of a normal B cell (HMY2. CIR), the lymphoma is judged to be positive, and the minimally invasive early diagnosis efficiency is remarkably improved.

The invention provides an electroencephalogram data transmission method combining lossless and lossy compression, belongs to the field of electroencephalogram data transmission and compression processing, and is used for solving the problems of low transmission efficiency of pure lossless compression and easy loss of key diagnosis information of pure lossy compression in related technologies. According to the method, multi-dimensional features of electroencephalogram data are extracted, a key area and a non-key area are divided, lossless compression and lossy compression processing are adopted respectively, the area division proportion is dynamically adjusted in combination with transmission bandwidth, signal features and application scenes, and corresponding data are transmitted through dual protocols. The transmission efficiency can be improved while the clinical diagnosis marker and the core characteristics are reserved, and the scene adaptability and the transmission reliability are achieved at the same time.

The invention discloses an active tuberculosis diagnostic marker, a kit and application thereof. In particular to application of a reagent for detecting a diagnostic marker in preparation of a kit for diagnosing active tuberculosis, the diagnostic marker is a biomarker TRIM22 in a blood sample, and the sequence of the TRIM22 is as shown in SEQ ID NO: 1. According to the invention, TRIM22 in a blood sample is used as a biomarker for detecting active tuberculosis for the first time. Results of ROC curve analysis show that the expression level of TRIM22 in whole blood has good sensitivity and specificity for active tuberculosis diagnosis. Therefore, the invention overcomes the defects of low detection rate, long time consumption and the like of the existing active tuberculosis diagnosis, has the characteristics of good specificity and high sensitivity, and has good clinical application value for the auxiliary diagnosis of the active tuberculosis.

The invention discloses application of GPR1 as a target spot in preparation of endometriosis related diagnosis and / or treatment preparations, and belongs to the technical field of biological medicines. The invention provides application of a GPR1 target spot serving as a diagnostic marker in preparation of a reagent or a kit for diagnosing endometriosis. The endometriosis is selected from one of a uterus-sacral ligament type endometriosis, a peritoneal type endometriosis, a rectum-vagina type endometriosis, a deep infiltration type endometriosis and an ovarian type endometriosis. The invention discovers that the expression of GPR1 in endometriosis tissues and cells is obviously increased, which prompts that GPR1 can be used as a diagnostic marker of endometriosis. In-vitro and in-vivo models find that the knockout of GPR1 significantly inhibits the proliferation, migration and invasion ability of hEM15A cells and the growth of ectopic lesions in animals, indicating that GPR1 can be used as a new intervention target for clinical treatment of endometriosis.

The invention discloses application of annular RNACirc3426 as a diagnostic marker and a therapeutic target of colorectal cancer. Experiments show that the Circ3426 is highly expressed in colorectal cancer cells and patient serum, and prove that the Circ3426 has good stability, and an ROC curve shows that the Circ3426 has good capacity of diagnosing colorectal cancer. Meanwhile, it is found that the molecule can promote migration and invasion ability of colorectal cancer cells, nude mouse subcutaneous tumor formation experiments prove that knock-down Circ3426 inhibits growth of tumors, and it is indicated that the molecule can serve as a treatment target of colorectal cancer. The invention provides a new diagnostic marker and a treatment target for colorectal cancer, and provides a new thought and direction for CRC diagnosis and treatment.

The invention discloses an application of a circRNA molecule as a diagnostic marker in a cell senescence diagnostic kit and an application of the circRNA molecule as a cell senescence treatment target. According to the application disclosed by the invention, the circHERC1 is found to be low in expression in natural aging and aging-inducing cell models, and the circHERC1 is over-expressed in endothelial cells, so that the multiplication capacity of the endothelial cells can be improved, the telomere length of the cells can be effectively prolonged, telomerase can be activated, the positive rate of beta-galactosidase of the cells can be reduced, and the expression quantity of aging-related proteins can be reduced.

The invention relates to a novel method for identifying a diagnostic marker peak of protein citrullination by mass spectrometry. A gas phase fragmentation pathway of citrullinated peptide is explored, a characteristic neutral loss is found, namely, the neutral loss of 43.0058 Da is matched with release of an isocyanate group of citrullinated ureido, the two modifications can be distinguished when the corresponding neutral loss is detected, and citrullinated modification can be accurately and quickly confirmed. When secondary mass spectrum data are retrieved, an anti-library is additionally added to calculate the false positive rate caused by random matching, and a common pollution library is added into a database to eliminate the influence of pollution protein in an identification result; the mass error tolerance is set in a targeted manner, and the accuracy of mass spectrum data retrieval and the diagnosis accuracy of protein citrullination are improved. The process of converting arginine into citrulline can be diagnosed with high specificity, the technology is a key technology for realizing polypeptide sequencing and post-translational modification analysis, and the specific citrulline part in the protein can be determined.

The invention provides a multi-element machine learning model-based cross-species lung disease characteristic gene screening method and system, an electronic system and a storage device. The method comprises the following steps of: acquiring single cell / transcriptome data related to mouse lung diseases from a public database and preprocessing the single cell / transcriptome data; training the model by adopting six machine learning algorithms and outputting a gene importance score; calculating the weight according to the model performance and normalizing the score; and integrating the cross-species scores through a weighted fusion formula, and outputting a feature gene list and a visual report. The system comprises a data acquisition and preprocessing module, a multi-element machine learning model training module, a weight calculation and normalization module, a cross-species comprehensive scoring module and a result output module. The screening accuracy, stability and generalization ability are improved through multi-algorithm integration and cross-species fusion, and the method can be widely applied to the fields of mechanism research of lung diseases, diagnosis marker development and drug target verification.

The invention belongs to the technical field of biomedicine, and particularly relates to application of DHX58 as a diagnostic marker and a therapeutic target of rheumatoid arthritis. Experiments prove that the DXH58 level in rheumatoid arthritis involved parts such as serum and synovial tissues of rheumatoid arthritis patients is remarkably increased, DHX58 and rheumatoid arthritis are positively correlated, and the DHX58 gene or DHX58 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of rheumatoid arthritis. Experiments prove that the targeted DHX58 can be used as an effective way for treating rheumatoid arthritis. The application has important meanings for researching the effect of DHX58 in rheumatoid arthritis, understanding the mechanism of RA disease and developing a new treatment strategy.

The present disclosure reveals a process for the determination of a risk for the development of cardiovascular disease (CVD) in the future from quantitative analysis of four specific IgG N-glycans isolated from a blood sample of examined human subjects. Said four specific glycans were found to be significant diagnostic markers by statistical analysis of the results obtained from previously performed clinical trials that revealed the variation of quantitative IgG glycans content in the blood plasma in a cohort of normal subjects, versus, those who experienced CVD clinical manifestations. From this analysis, a new numerical model was developed which enables the calculation of the CVD risk parameter (CVDR). The numerical value for CVDR obtained after the inclusion of the result of said four key glycans, obtained from the blood analysis, gives an assessment of the eventual CVD development in the examined subject in the future.

The invention belongs to the technical field of medicines, and particularly discloses a biomarker for detecting kidney fibrosis related diseases and application of the biomarker. The biomarker comprises serum copper cyanin, or the serum copper cyanin and serum creatinine. Compared with other methods for diagnosing renal fibrosis, the serum cupreuloplasmin has the following three advantages: 1, compared with a conventional diagnostic marker (such as serum creatinine), the cupreuloplasmin can detect up-regulation in the serum of a patient suffering from early chronic kidney diseases, and can be combined with an existing mature diagnostic marker for detection; secondly, compared with renal tissue pathologic biopsy, the use of the copper cyanin as the diagnostic marker has non-invasiveness, and only a small amount or even a trace amount of patient serum is needed, so that the harm to the body health of the patient is avoided; and thirdly, compared with a nuclear magnetic resonance method for analyzing the metabolic components of the urine, the method for detecting the markers in the serum is lower in cost, more flexible, high in timeliness and easier to popularize.

The invention belongs to the technical field of biological medicine, and particularly relates to application of macrophage LSR gene and / or LSR protein in preparation of drugs and diagnostic products for preventing and / or treating diabetic nephropathy. Research finds that the LSR deletion of macrophages aggravates renal injury by promoting inflammatory response of diabetic nephropathy and increasing lipid renal toxicity; on the contrary, after the LSR expression of the macrophages is recovered, the inflammatory response and lipid droplet deposition of the kidney of the diabetic nephropathy mouse can be effectively reduced, and meanwhile, the kidney injury is improved. Cell experiments show that LSR deletion of macrophages can activate a YAP signal channel to increase secretion of inflammatory factors and reduce low-density lipoprotein uptake at the same time. Therefore, the macrophage LSR can be used as a diabetic nephropathy drug target, a gene therapy target gene and an auxiliary diagnosis marker, and a new theoretical basis and an intervention strategy are provided for prevention and treatment of the disease.

The invention discloses a diagnostic marker for Parkinson's disease, application of the diagnostic marker and a heteropolymer detection method, and relates to the technical field of biology. The diagnostic marker is a protein heterozygous aggregate in a brain-derived exosome, and the protein heterozygous aggregate comprises alpha-synuclein and amylin. The invention also provides application of a reagent for detecting the diagnostic marker in preparation of a diagnostic product for Parkinson's disease. According to the present invention, the research results show that the important biomarker protein aggregate in the Parkinson's disease diagnosis is not the aggregate simply formed by polymerizing the alpha-Synuclein (aS) protein, but is doped with the other easily aggregated protein-amylin (Amylin); a heteropolymer composed of aS and Amylin is adopted as a biomarker, and the diagnosis efficiency on the Parkinson's disease can be effectively improved.

The present invention relates to: a biomarker composition comprising AMPD3 for predicting sensitivity to a therapeutic agent for neurofibromatosis (NF1); a pharmaceutical composition comprising an AMPD3 inhibitor for preventing or treating NF1; and use thereof. The composition according to one aspect is highly useful as a diagnostic marker for therapeutic agent sensitivity in patients with NF1, and can be used as a new therapeutic target for NF1.

The invention discloses application of a diagnostic marker in preparation of a rheumatoid arthritis diagnostic product and a diagnostic system, and relates to the technical field of rheumatoid arthritis diagnosis. And the diagnostic marker comprises KMT2B, KMT2C, IFITM3, ECHS1, LYMPH%, MONO%, PDW, Path.CAST, RDW and RDW%. The diagnosis marker provided by the invention has extremely high diagnosis efficiency and has a good application prospect in the field of diagnosis of rheumatoid arthritis.

The invention provides an application of human source circular RNA hsacirc0083796 in preparation of a diagnostic reagent or a medicine for diagnosing and / or treating aortic dissection. The invention also provides a kit for diagnosing the aortic dissection. The invention also provides a pharmaceutical composition for treating aortic dissection. According to the application of the human source circular RNA in preparation of heart disease related products, the related heart disease related circular RNA (circled-Frizzled class receptor 3, hsacirc0083796) is one of circular RNAs with the highest expression quantity in the blood of aortic dissection patients and has high conservative property, the function of the circular RNA is closely related to heart diseases, and the circular RNA has a good application prospect in preparation of heart disease related products. The method has great significance in diagnosis and treatment of heart diseases. Meanwhile, due to the stable and specific properties of the circular RNA, compared with other types of markers, the circular RNA has larger abundance in body fluid of a patient and more obvious change, so that the circular RNA has the potential of becoming a novel diagnostic marker.

The invention relates to a circulating free DNA (cfDNA)-based early-stage prostate cancer diagnosis marker, an evaluation system and application. According to the early-stage prostate cancer diagnosis marker, 25 cfDNA characteristic markers are obtained through fluorescent quantification, nucleic acid protein analysis, cfDNA sequencing and classification model construction, evaluation and screening. The AUC of an ROC curve of an early-stage prostate cancer evaluation model of the cfDNA characteristic marker is as high as 100%, which indicates that the biomarker has a good indication effect in the aspect of diagnosis of early-stage prostate cancer and can be used as a non-invasive biomarker for detection of early-stage prostate cancer. The method is noninvasive, convenient to operate, high in accuracy and capable of effectively distinguishing cfDNA feature differences of prostatic cancer patients and healthy people and efficiently recognizing early prostatic cancer patients.

The invention provides a diagnostic marker for metabolic syndrome and preclinical stage thereof, and the diagnostic marker or a plasma small molecule metabolism biomarker consists of the following substances: pyrimidine, (S)-beta-aminoisobutyric acid, 3-hydroxybutyric acid, L-serine, guanidine acetic acid, 3-hydroxyisovaleric acid, L-homoserine, L-cysteine, piperidine acid, hypotaurine and creatinine. The beverage is prepared from phenylacetic acid, erythritol, picolinic acid, taurine, pyroglutamic acid, lemonic acid, malic acid, tyramine, isonicotinic acid, o-phosphoethanolamine, L-glutamine, salicylic acid and D-glucose. The invention also provides a kit for detecting the plasma small molecule metabolism biomarker composition, the spectrum peak intensity of the obtained plasma small molecule metabolism biomarker is detected, the risk score of whether each subject is MetS or pre-MetS is calculated, and then whether the subject is MetS or pre-MetS is predicted. According to the invention, efficient and rapid diagnosis of the metabolic syndrome and the preclinical stage thereof is realized.

The invention relates to the field of biological medicine and data analysis, in particular to a method and a system for screening Alzheimer's disease diagnostic markers. The invention provides a method and a system for screening Alzheimer's disease diagnostic markers, which are used for searching key genes in AD pathology based on Mendel randomization (SMR) analysis of summarized data in combination with a multi-omics (risk gene methylation, expression and protein abundance information) research method, and revealing a regulation mechanism of the key genes in AD pathology. According to the method and the system provided by the invention, the diagnosis marker and the treatment target of the AD are further accurate, the understanding of a molecular mechanism in the AD disease is deepened, a new treatment target is found, an innovative strategy and a tool are provided for individualized treatment, and the life quality of a patient is finally improved.

The invention discloses a diagnostic marker combination for senile weakness and application thereof, and relates to the technical field of biological medicines. The diagnostic marker combination comprises a GDF15 protein, an FABP4 protein, an ITGA11 protein, an LEP protein, an REN protein and a CTSB protein. Aiming at the urgent medical problems that no unified elderly weakness diagnosis standard exists in the world at present, a blank exists on the basis of blood diagnosis indexes, and serious obstacles are brought to community screening, clinical decision making and health management, on the basis of sample screening and sample verification research, a systematic epidemiology method is applied, and the elderly weakness diagnosis standard is established. The biomarkers are identified in a multi-level and omnibearing manner, and a diagnostic marker combination for senile weakness and a diagnostic product based on biomolecules are developed so as to be applied to community screening and clinical diagnosis and lay a key foundation for disease prevention and treatment and clinical application.